Company / Corporate
NKGen Biotech, Inc..
Follow NKGen Biotech, Inc.NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing autologous, allogeneic and CAR-NK natural killer cell therapies using its proprietary SNK platform.[1]
02Deals
Deals on Carrywatch
Every deal that names NKGen Biotech, Inc., and its role in each.
NKGen Biotech, Inc. / NKMax Co., Ltd.
NKGen Biotech takes control of NKMax in completed acquisition
See deal detailsGraf Acquisition Corp. IV / NKGen Biotech, Inc.
Graf Acquisition Corp. IV and NKGen Biotech complete business combination
See deal detailsDeal Web
NKGen Biotech, Inc. and 1 firm it shares a posted deal with, and the path to any other firm.
Financials
4 fiscal years of figures as NKGen Biotech, Inc. reported them.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01NKGen Biotech, Inc. Unaudited Condensed Consolidated Financial Statements
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming NKGen Biotech, Inc.:
- P01
- P02